ANTABIO

France - Labege

• 13/12/2023
• Series B
• $26,976,000

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. The company’s lead product is expected to enter the clinic in 2019 with a fast track to anticipated marketing approval. Antabio has built a best in class, international team of experts in the field and is currently seeking to raise additional funds to progress its pipeline up to the next value inflection point. Our company is also looking to in-license additional assets focused on Gram-negative antibiotic resistant therapies. Please visit www.antabio.com and follow us on Twitter @antabio

Related People

Marc LemonnierFounder

France - Greater Toulouse Metropolitan Area

Founding CEO of ANTABIO SAS, a private biopharma company developing novel therapies to treat Drug-Resistant Infections by WHO's critical priority pathogens. Officer at BEAM Alliance (Biotech companies in Europe combating AntiMicrobial Resistance). Member of the Scientific Advisory Board of JPIAMR (Joint Programming Initiative on Antimicrobial Resistance ).

LinkedIn https://www.linkedin.com/in/marclemonnier/